EGFR and non-small cell lung carcinoma: Increased expression of YPEL5, coding for a member of the carboxy-terminal to LisH (CTLH) complex, has been reported in erlotinib-treated EGFR-mutant non-small cell lung cancer [65], while recurrent YPEL5-PPP1CB fusion has been reported for chronic lymphocytic leukaemia [66].